Skip to main content
main-content

The independent medical news service

Breast cancer

04-03-2021 | Oncology | News | Article

‘Profound’ estradiol reduction with GnRHa in MALE breast cancer patients

The addition of gonadotropin-releasing hormone analog to tamoxifen or an aromatase inhibitor decreases estradiol levels of men with hormone receptor-positive breast cancer, phase 2 trial data show.

03-03-2021 | Oncology | Highlight | Article

Screening by clinical breast examination feasible for low, middle income countries

Breast cancer screening by clinical breast examination is a viable approach in low and middle income countries, suggests an Indian cluster randomized controlled trial.

26-02-2021 | Oncology | News | Article

Risk tool predicts chemotherapy toxicity in older breast cancer patients

US researchers have developed the Cancer and Aging Research Group–Breast Cancer score to help predict grade 3–5 chemotherapy-related toxicities in older patients with early-stage breast cancer.

23-02-2021 | Oncology | News | Article

21-gene recurrence score underperforms in Black women with breast cancer

Black women with breast cancer are more likely than non-Hispanic White women to have a high-risk 21-gene Oncotype DX Breast Recurrence Score, and are more likely to die of breast cancer than their non-Hispanic White counterparts with a comparable score, US research shows.

15-02-2021 | Oncology | News | Article

Radiotherapy activity changed significantly during first COVID-19 peak

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

02-02-2021 | Oncology | News | Article

Psychological distress high in patients with cancer during COVID-19 pandemic

Two independent studies presented at the IASLC 2020 World Conference on Lung Cancer have highlighted the heightened psychological distress experienced by patients with cancer – especially those with lung cancer – during the COVID-19 pandemic.

29-01-2021 | Oncology | News | Article

SOPHIA: Margetuximab boosts HER2-positive advanced breast cancer PFS

Treatment with the novel HER2-targeted agent margetuximab improves the outcomes of heavily pretreated patients with HER2-positive advanced breast cancer, indicate phase 3 trial results.

27-01-2021 | Oncology | News | Article

Population-based risk estimates for breast cancer genes reported

Two analyses have provided population-level estimates of the risk for breast cancer associated with known or suspected susceptibility genes.

25-01-2021 | Oncology | News | Article

Predictive factors for ONJ risk with zoledronic acid identified

The risk for osteonecrosis of the jaw following zoledronic acid treatment in patients with bone metastases is associated with cancer type, oral health, and dosing frequency, US researchers report.

21-01-2021 | Oncology | News | Article

Statins may mitigate anthracycline, trastuzumab cardiotoxicity risk

Statin use is associated with a reduced risk for heart failure in women with early breast cancer receiving anthracycline- or trastuzumab-based chemotherapy, report Canadian researchers.

19-01-2021 | Oncology | News | Article

No PFS advantage for palbociclib plus endocrine therapy vs capecitabine

Palbociclib plus endocrine therapy does not improve progression-free survival compared with capecitabine in women with aromatase inhibitor-resistant metastatic breast cancer, results of the phase 3 PEARL study show.

14-01-2021 | Oncology | News | Article

Real-world data support efficacy of SABR for extracranial oligometastases

The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

12-01-2021 | Oncology | News | Article

Subcutaneous pertuzumab, trastuzumab noninferior to intravenous delivery

Subcutaneous administration of pertuzumab and trastuzumab generates similar pertuzumab serum trough concentrations to those seen with intravenous pertuzumab plus trastuzumab in women with HER2-positive breast cancer, research shows.

08-01-2021 | Oncology | News | Article

PARP inhibitor use associated with MDS, AML risk

The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.

05-01-2021 | Oncology | News | Article

Capecitabine maintenance may improve TNBC outcomes

Maintenance therapy with low-dose capecitabine significantly reduces the risk for relapse or death in women with early-stage triple-negative breast cancer, show data from the phase 3 SYSUCC-001 trial.

24-12-2020 | Oncology | News | Article

HRQoL effects of breast cancer prognosis, treatment predict mortality risk

The health-related quality of life of patients with ductal carcinoma in situ or invasive breast cancer is impaired by their prognosis and treatment, and measuring the extent of impairment could help predict mortality risk, research suggests.

24-12-2020 | Oncology | News | Article

EMA adopts positive opinions for breast, lung, GU cancer indications

Read more about these decisions here

23-12-2020 | Oncology | News | Article

FDA announces breast, lung, prostate cancer approvals

Click through to find out more about the approved drugs

22-12-2020 | Oncology | News | Article

​​​​​​​TNBC patients benefit from pembrolizumab in combination with various chemotherapies

Beneficial outcomes with pembrolizumab plus chemotherapy persist with different types of chemotherapy in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer, exploratory analysis of the KEYNOTE-355 trial suggests.

21-12-2020 | Oncology | News | Article

Early data signal immunopriming effect of bevacizumab in advanced breast cancer

Combined treatment with durvalumab plus bevacizumab could benefit women with HER2-negative advanced breast cancer who have progressed on bevacizumab maintenance, shows a phase 1b trial.

Image Credits